Essen

• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 5 2026-01-21 Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
• Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou … Recruiting
  2025-521144-38-00 4 2025-12-23 Primary Central Nervous System Lymphoma
• Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residua … Recruiting
  2024-512503-39-00 6 2025-12-19 Arm A (AML): Newly diagnosed de novo Acute myeloid leukemia (AML) or M
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer Recruiting
  2025-521003-52-00 9 2025-12-19 HER2 Expressing Advanced Breast Cancer
• A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia Recruiting
  2025-521692-31-00 5 2025-12-19 Chronic Primary Immune Thrombocytopenia
• Nivolumab in combination with cisplatin and 5-fluorouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carc … Recruiting
  2022-500676-59-00 4 2025-12-18 EBV-positive nasopharyngeal carcinoma
• To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan … Recruiting
  2025-521128-31-00 9 2025-12-18 Locally Advanced or Metastatic Estrogen Receptor-Positive, human epide
• ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha … Recruiting
  2025-522718-22-00 4 2025-12-16 Gastroesophageal Adenocarcinoma
• A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and ch … Recruiting
  2025-523009-14-00 4 2025-12-16 Bronchiectasis with chronic pseudomonas aeruginosa colonization
• QUADvance: Advancing Allogeneic Quad-CAR01-T Therapy in Hard-to-Treat B-Cell Cancers Recruiting
  2025-521735-36-00 7 2025-12-15 Relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) or chronic
• A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and … Recruiting
  2025-521738-27-00 4 2025-12-15 Recurrent Metastatic Head and Neck Cancer
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• Atacicept in Multiple Glomerular Diseases Recruiting
  2024-518465-10-00 4 2025-12-12 Multiple Autoimmune Glomerular Diseases
• A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting
  2024-512904-21-00 4 2025-12-10 Migraine
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• A Clinical Trial of Tirzepatide (LY3298176) in Subjects With Overweight or Obesity and PCOS-related Ovarian Dysfunction (PERIODS) Recruiting
  2024-515982-32-00 6 2025-12-09 Overweight or Obesity
• An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat … Recruiting
  2024-519913-76-00 4 2025-12-09 PDL1-negative metastatic triple-negative breast cancer
• FUTURE Recruiting
  2024-517573-24-00 4 2025-12-08 Colorectal cancer
• A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination … Recruiting
  2024-517261-16-00 9 2025-12-05 Advanced solid tumors
• A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program … Recruiting
  2025-521281-97-00 5 2025-12-02 Non-Small Cell Lung Cancer (NSCLC)
• A Phase 2 Randomized, Double-blind Placebo-Controlled Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety and Efficacy of WIN378 … Recruiting
  2025-521391-58-00 4 2025-11-28 Asthma
• A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting
  2024-519727-18-00 1 2025-11-25 Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer
• Safety and Efficacy of Tarperprumig in Adult Participants with ANCA-Associated Vasculitis Recruiting
  2025-521706-17-00 4 2025-11-25 Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Showing 193–216 of 965 trials